CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor /[177Lu]Lu-Pentixather
Open Access
- 7 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 49 (2), 481-491
- https://doi.org/10.1007/s00259-021-05196-4
Abstract
Purpose CXCR4 (over)expression is found in multiple human cancer types, while expression is low or absent in healthy tissue. In glioblastoma it is associated with a poor prognosis and more extensive infiltrative phenotype. CXCR4 can be targeted by the diagnostic PET agent [68Ga]Ga-Pentixafor and its therapeutic counterpart [177Lu]Lu-Pentixather. We aimed to investigate the expression of CXCR4 in glioblastoma tissue to further examine the potential of these PET agents. Methods CXCR4 mRNA expression was examined using the R2 genomics platform. Glioblastoma tissue cores were stained for CXCR4. CXCR4 staining in tumor cells was scored. Stained tissue components (cytoplasm and/or nuclei of the tumor cells and blood vessels) were documented. Clinical characteristics and information on IDH and MGMT promoter methylation status were collected. Seven pilot patients with recurrent glioblastoma underwent [68Ga]Ga-Pentixafor PET; residual resected tissue was stained for CXCR4. Results Two large mRNA datasets (N = 284; N = 540) were assesed. Of the 191 glioblastomas, 426 cores were analyzed using immunohistochemistry. Seventy-eight cores (23 tumors) were CXCR4 negative, while 18 cores (5 tumors) had both strong and extensive staining. The remaining 330 cores (163 tumors) showed a large inter- and intra-tumor variation for CXCR4 expression; also seen in the resected tissue of the seven pilot patients—not directly translatable to [68Ga]Ga-Pentixafor PET results. Both mRNA and immunohistochemical analysis showed CXCR4 negative normal brain tissue and no significant correlation between CXCR4 expression and IDH or MGMT status or survival. Conclusion Using immunohistochemistry, high CXCR4 expression was found in a subset of glioblastomas as well as a large inter- and intra-tumor variation. Caution should be exercised in directly translating ex vivo CXCR4 expression to PET agent uptake. However, when high CXCR4 expression can be identified with [68Ga]Ga-Pentixafor, these patients might be good candidates for targeted radionuclide therapy with [177Lu]Lu-Pentixather in the future.Keywords
Funding Information
- T&P Bohnenn Fund
This publication has 29 references indexed in Scilit:
- The role of the CXCR4 cell surface chemokine receptor in glioma biologyJournal of Neuro-Oncology, 2013
- [18F]-fluoro-ethyl-l-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is gliomaNeuro-Oncology, 2013
- Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than HistologyCancer Research, 2009
- Expression of CXCL12 on pseudopalisading cells and proliferating microvessels in glioblastomas: An accelerated growth factor in glioblastomasInternational Journal of Oncology, 2009
- CXCR4 EXPRESSION IS ELEVATED IN GLIOBLASTOMA MULTIFORME AND CORRELATES WITH AN INCREASE IN INTENSITY AND EXTENT OF PERITUMORAL T2-WEIGHTED MAGNETIC RESONANCE IMAGING SIGNAL ABNORMALITIESNeurosurgery, 2008
- Promoter hypermethylation‐mediated down‐regulation of CXCL12 in human astrocytomaJournal of Neuroscience Research, 2008
- PREFERENTIAL EXPRESSION OF CHEMOKINE RECEPTOR CXCR4 BY HIGHLY MALIGNANT HUMAN GLIOMAS AND ITS ASSOCIATION WITH POOR PATIENT SURVIVALNeurosurgery, 2007
- Expression of CXC chemokine receptors 1–5 and their ligands in human glioma tissues: Role of CXCR4 and SDF1 in glioma cell proliferation and migrationNeurochemistry International, 2006
- Widespread CXCR4 Activation in Astrocytomas Revealed by Phospho-CXCR4-Specific AntibodiesCancer Research, 2005
- Molecular characterization of CXCR–4: A potential brain tumor-associated geneJournal of Surgical Oncology, 1998